1
|
Futagami S, Agawa S, Nakamura K, Watanabe Y, Habiro M, Kawawa R, Yamawaki H, Tsushima R, Kirita K, Akimoto T, Ueki N, Tomohide T, Itokawa N, Suzuki N, Naito Y, Takeuchi K, Kashiro A, Ohta R, Mizutani S, Taniai N, Yoshida H, Iwakiri K, Honda K. Apolipoprotein A2 isoforms associated with exocrine pancreatic insufficiency in early chronic pancreatitis. J Gastroenterol Hepatol 2023; 38:1949-1957. [PMID: 37501507 DOI: 10.1111/jgh.16302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 05/17/2023] [Accepted: 07/04/2023] [Indexed: 07/29/2023]
Abstract
BACKGROUND AND AIM Apolipoprotein A2 (apoA2) isoforms have been reported to undergo the aberrant processing in pancreatic cancer and pancreatic risk populations compared with that in healthy subjects. This study aimed to clarify whether apoA2 isoforms were as useful as N-benzoyl-p-aminobenzoic acid (BT-PABA) test for exocrine pancreatic dysfunction markers in patients with early chronic pancreatitis (ECP). METHODS Fifty consecutive patients with functional dyspepsia with pancreatic enzyme abnormalities (FD-P) (n = 18), with ECP (n = 20), and asymptomatic patients with pancreatic enzyme abnormalities (AP-P) (n = 12) based on the Rome IV classification and the Japan Pancreatic Association were enrolled in this study. The enrolled patients were evaluated using endoscopic ultrasonography and endoscopic ultrasonography elastography. Five pancreatic enzymes were estimated. Pancreatic exocrine function was analyzed using the BT-PABA test. Lighter and heavier apoA2 isoforms, AT and ATQ levels were measured by enzyme-linked immunosorbent assay methods. RESULTS There were no significant differences in clinical characteristics such as age, gender, body mass index, alcohol consumption and smoking among patients with AP-P, FD-P, and ECP. The BT-PABA test and lighter apoA2 isoform, AT level in the enrolled patients had a significant correlation (P < 0.01). The BT-PABA test in patients with ECP was significantly lower (P = 0.04) than that in AP-P. ApoA2-AT level in patients with ECP was lower than that in AP-P, albeit, insignificantly. Interestingly, apo A2-AT level was significantly (P = 0.041) associated with exocrine pancreatic insufficiency by multiple logistic regression analysis. CONCLUSIONS ApoA2-AT level is a useful tool to evaluate exocrine pancreatic insufficiency in the early stage of chronic pancreatitis.
Collapse
Affiliation(s)
- Seiji Futagami
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | - Shuhei Agawa
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | - Ken Nakamura
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | | | - Mayu Habiro
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | - Rie Kawawa
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | - Hiroshi Yamawaki
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | - Rina Tsushima
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | - Kumiko Kirita
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | - Teppei Akimoto
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | - Nobue Ueki
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | - Tanabe Tomohide
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | - Norio Itokawa
- Division of Gastroenterology, Nippon Medical School, Tokyo, Japan
| | - Nami Suzuki
- Department of Bioregulation, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
| | - Yutaka Naito
- Department of Bioregulation, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
| | - Keiko Takeuchi
- Department of Bioregulation, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
| | - Ayumi Kashiro
- Department of Bioregulation, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
| | - Ryu Ohta
- Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan
| | - Satoshi Mizutani
- Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan
| | - Nobuhiko Taniai
- Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan
| | - Hiroshi Yoshida
- Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, Tokyo, Japan
| | | | - Kazufumi Honda
- Department of Bioregulation, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan
| |
Collapse
|
2
|
Li Z, Zhang Q, Liu X, Zhao M. Recombinant Humanized IgG1 Antibody Promotes Reverse Cholesterol Transport through FcRn-ERK1/2-PPARα Pathway in Hepatocytes. Int J Mol Sci 2022; 23:ijms232314607. [PMID: 36498935 PMCID: PMC9736681 DOI: 10.3390/ijms232314607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 11/13/2022] [Accepted: 11/17/2022] [Indexed: 11/24/2022] Open
Abstract
Hyperlipidemia-associated lipid disorders are considered the cause of atherosclerotic cardiovascular disease. Reverse cholesterol transport (RCT) is a mechanism by which excess peripheral cholesterol is transported to the liver and further converted into bile acid for excretion from the body in feces, which contributes to reducing hyperlipidemia as well as cardiovascular disease. We previously found that the recombinant humanized IgG1 antibody promotes macrophages to engulf lipids and increases cholesterol efflux to high-density lipoprotein (HDL) through ATP-binding cassette sub-family A1 (ABCA1), one of the key proteins related to RCT. In the present study, we explored other RCT related proteins expression on hepatocytes, including scavenger receptor class B type I (SR-BI), apolipoprotein A-I (ApoA-I), and apolipoprotein A-II (ApoA-II), and its modulation mechanism involved. We confirmed that the recombinant humanized IgG1 antibody selectively activated ERK1/2 to upregulate SR-BI, ApoA-I, and ApoA-II expression in mice liver and human hepatocellular carcinoma cell lines HepG2 cells. The rate-limiting enzymes of bile acid synthesis, including cholesterol 7α-hydroxylase (CYP7A1) and sterol 27-hydroxylase (CYP27A1), exhibited a significant increase when treated with the recombinant humanized IgG1 antibody, as well as increased excretion of bile acids in feces. Besides, abolishment or mutation of peroxisome proliferator-activated receptor α (PPARα)/RXR binding site on SR-BI promoter eliminated SR-BI reporter gene luciferase activity even in the presence of the recombinant humanized IgG1 antibody. Knock down the neonatal Fc receptor (FcRn) on hepatocytes impaired the effect of recombinant humanized IgG1 antibody on activation of ERK1/2, as well as upregulation of SR-BI, ApoA-I, and ApoA-II expression. In conclusion, one of the mechanisms on the recombinant humanized IgG1 antibody attenuates hyperlipidemia in ApoE-/- mice model fed with high-fat-diet might be through reinforcement of liver RCT function in an FcRn-ERK1/2-PPARα dependent manner.
Collapse
Affiliation(s)
- Zhonghao Li
- Key Lab for Shock and Microcirculation Research of Guangdong, Department of Pathophysiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
| | - Qi Zhang
- The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
| | - Xianyan Liu
- Key Lab for Shock and Microcirculation Research of Guangdong, Department of Pathophysiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
| | - Ming Zhao
- Key Lab for Shock and Microcirculation Research of Guangdong, Department of Pathophysiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
- Correspondence:
| |
Collapse
|
3
|
Lin YH, Liu YC, Chen CY, Chi HC, Wu MH, Huang PS, Chang CC, Lin TK, Yeh CT, Lin KH. LPAL2 Suppresses Tumor Growth and Metastasis of Hepatocellular Carcinoma by Modulating MMP9 Expression. Cells 2022; 11:cells11162610. [PMID: 36010685 PMCID: PMC9406458 DOI: 10.3390/cells11162610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 08/11/2022] [Accepted: 08/18/2022] [Indexed: 11/16/2022] Open
Abstract
Tumor metastasis is a complex process modulated by both intrinsic and extrinsic factors that ultimately result in poorer patient outcomes, including diminished survival. Pseudogene-derived long non-coding RNAs (lncRNA) play important roles in cancer progression. In the current study, we found that the pseudogene-derived lncRNA LPAL2 is downregulated in hepatocellular carcinoma (HCC) tissues, and further showed that elevated LPAL2 expression is positively correlated with survival outcome. The knockdown of LPAL2 in hepatoma cells induced tumor formation, migration, invasion, sphere formation, and drug resistance. Metalloproteinase 9 (MMP9) was identified as an LPAL2-regulated target gene, consistent with clinical findings that LPAL2 expression is significantly associated with MMP9 expression. Furthermore, patients with a higher expression of LPAL2 and lower expression of MMP9 (LPAL2-high/MMP9-low) had a higher survival rate than those with other combinations. Collectively, our findings establish LPAL2 as a novel tumor suppressor in HCC, and suggest targeting LPAL2 and MMP9 as a therapeutic approach for the treatment of HCC.
Collapse
Affiliation(s)
- Yang-Hsiang Lin
- Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan 333, Taiwan
| | - Yu-Chin Liu
- Molecular Medicine Research Center, Chang Gung University, Taoyuan 244, Taiwan
- Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan
- Department of Biochemistry, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
| | - Cheng-Yi Chen
- Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
| | - Hsiang-Cheng Chi
- Graduate Institute of Integrated Medicine, China Medical University, Taichung 40447, Taiwan
- Chinese Medicine Research Center, China Medical University, Taichung 406040, Taiwan
| | - Meng-Han Wu
- Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan
| | - Po-Shuan Huang
- Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan
| | - Cheng-Chih Chang
- Department of General Surgery, Chang Gung Memorial Hospital at Chia-yi, Chia-yi 613, Taiwan
| | - Tzu-Kang Lin
- Neurosurgery, School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City 24205, Taiwan
- Neurosurgery, Department of Surgery, Fu Jen Catholic University Hospital, New Taipei City 24352, Taiwan
| | - Chau-Ting Yeh
- Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan 333, Taiwan
- Correspondence: (C.-T.Y.); (K.-H.L.); Tel./Fax: +886-3-3281200 (ext. 8102) (C.-T.Y.); +886-3-2118263 (K.-H.L.)
| | - Kwang-Huei Lin
- Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan 333, Taiwan
- Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan
- Department of Biochemistry, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
- Neurosurgery, Department of Surgery, Fu Jen Catholic University Hospital, New Taipei City 24352, Taiwan
- Correspondence: (C.-T.Y.); (K.-H.L.); Tel./Fax: +886-3-3281200 (ext. 8102) (C.-T.Y.); +886-3-2118263 (K.-H.L.)
| |
Collapse
|
4
|
Abaj F, Esmaeily Z, Naeini Z, Rafiee M, Koohdani F. Dietary acid load modifies the effects of ApoA2-265 T > C polymorphism on lipid profile and serum leptin and ghrelin levels among type 2 diabetic patients. BMC Endocr Disord 2022; 22:190. [PMID: 35883173 PMCID: PMC9316730 DOI: 10.1186/s12902-022-01083-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/01/2022] [Accepted: 06/23/2022] [Indexed: 12/15/2022] Open
Abstract
This investigation with aimed the effect of APOA2-265 T > C polymorphism and dietary acid load (DAL) as either potential renal acid load (PRAL) and net endogenous acid production (NEAP) intake interaction on metabolic markers in type 2 diabetes mellitus (T2DM). In present cross-sectional study, 737 patients with T2DM (290 men and 447 women) were enlisted from diabetes centers in Tehran. The dietary intakes of all participants during the last year was acquired by a validated semi-quantitative food frequency (FFQ) questionnaire. Polymerase chain reaction (PCR) was used for genotyping the APOA2-265 T > C. Biochemical indises containing leptin, ghrelin, total cholesterol (Bailey et al., J Clin Invest 97:1147-1453, 1996), low-density lipoprotein cholestrol (LDL-C), high-density lipoprotein cholestrol (HDL-C), triglyceride (TG), superoxide dismutase (SOD), high sensitivy C-reactive protein (hs-CRP), total antioxidant capacity (TAC), pentraxin-3 (PTX3), prostaglandin F2α (PGF2α) and interleukin 18 (IL18) were measured by standard method. Atherogenic indices (AIP, AC, CR-I, CR-II) were calculated. The gene-diet interactions were evaluated using an GLM. The frequency overall prevalence of rs5082 genotypes was 63.82 and 36.17% for T-allele and C-allele respectively. TG, Ghrelin, and hs-CRP concentrations were significantly higher among carriers with C allele than TT homozygotes. However, TC/CC genotypes have lower PTX3 than TT homozygotes (P < 0.05). C-allele carriers had highest mean of BMI (PNEAP=0.04, PPRAL = 0.006), WC (PNEAP=0.04, PPRAL = 0.04), TC (PNEAP=0.03, PPRAL = 0.01), ghrelin (PNEAP=0.01, PPRAL = 0.04), and leptin (PNEAP=0.04, PPRAL = 0.03) when placed in top tertiles of NEAP and PRAL.BMI, WC, TC, ghrelin, and leptin levels may be modified in C carriers by decreasing DAL, though, further investigations are required to confirm these findings.
Collapse
Affiliation(s)
- Faezeh Abaj
- Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
| | - Zahra Esmaeily
- Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
| | - Zeinab Naeini
- Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, PO Box: 141556117, Tehran, Iran
| | - Masoumeh Rafiee
- Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
| | - Fariba Koohdani
- Department of Cellular and Molecular Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, PO Box: 141556117, Tehran, Iran.
| |
Collapse
|
5
|
Dai J, Li Y, Kametani F, Cui X, Igarashi Y, Huo J, Miyahara H, Mori M, Higuchi K. Curcumin promotes AApoAII amyloidosis and peroxisome proliferation in mice by activating the PPARα signaling pathway. eLife 2021; 10:e63538. [PMID: 33496266 PMCID: PMC7880682 DOI: 10.7554/elife.63538] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Accepted: 01/10/2021] [Indexed: 12/16/2022] Open
Abstract
Curcumin is a polyphenol compound that exhibits multiple physiological activities. To elucidate the mechanisms by which curcumin affects systemic amyloidosis, we investigated amyloid deposition and molecular changes in a mouse model of amyloid apolipoprotein A-II (AApoAII) amyloidosis, in which mice were fed a curcumin-supplemented diet. Curcumin supplementation for 12 weeks significantly increased AApoAII amyloid deposition relative to controls, especially in the liver and spleen. Liver weights and plasma ApoA-II and high-density lipoprotein concentrations were significantly elevated in curcumin-supplemented groups. RNA-sequence analysis revealed that curcumin intake affected hepatic lipid metabolism via the peroxisome proliferator-activated receptor (PPAR) pathway, especially PPARα activation, resulting in increased Apoa2 mRNA expression. The increase in liver weights was due to activation of PPARα and peroxisome proliferation. Taken together, these results demonstrate that curcumin is a PPARα activator and may affect expression levels of proteins involved in amyloid deposition to influence amyloidosis and metabolism in a complex manner.
Collapse
Affiliation(s)
- Jian Dai
- Department of Neuro-health Innovation, Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu UniversityMatsumotoJapan
- Department of Pathology, the Xiehe Hospital of TangshanTangshanChina
| | - Ying Li
- Aging Biology, Department of Biomedical Engineering, Graduate School of Medicine, Science and Technology Shinshu UniversityMatsumotoJapan
| | - Fuyuki Kametani
- Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical ScienceTokyoJapan
| | - Xiaoran Cui
- Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of MedicineMatsumotoJapan
| | - Yuichi Igarashi
- Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of MedicineMatsumotoJapan
| | - Jia Huo
- Department of Orthopedic Surgery, the Third Hospital of Hebei Medical UniversityShijiazhuangChina
| | - Hiroki Miyahara
- Department of Neuro-health Innovation, Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu UniversityMatsumotoJapan
- Department of Aging Biology, Shinshu University School of MedicineMatsumotoJapan
| | - Masayuki Mori
- Department of Neuro-health Innovation, Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu UniversityMatsumotoJapan
- Department of Aging Biology, Shinshu University School of MedicineMatsumotoJapan
| | - Keiichi Higuchi
- Department of Neuro-health Innovation, Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu UniversityMatsumotoJapan
- Department of Aging Biology, Shinshu University School of MedicineMatsumotoJapan
| |
Collapse
|
6
|
McCullough A, Previs SF, Dasarathy J, Lee K, Osme A, Kim C, Ilchenko S, Lorkowski SW, Smith JD, Dasarathy S, Kasumov T. HDL flux is higher in patients with nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 2019; 317:E852-E862. [PMID: 31503515 PMCID: PMC6879863 DOI: 10.1152/ajpendo.00193.2019] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2019] [Revised: 08/09/2019] [Accepted: 08/25/2019] [Indexed: 12/13/2022]
Abstract
Altered lipid metabolism and inflammation are involved in the pathogenesis of both nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD). Even though high-density lipoprotein (HDL), a CVD protective marker, is decreased, whether HDL metabolism and function are perturbed in NAFLD are currently unknown. We examined the effect of NAFLD and disease severity on HDL metabolism and function in patients with biopsy-proven simple steatosis (SS), nonalcoholic steatohepatitis (NASH), and healthy controls. HDL turnover and HDL protein dynamics in SS (n = 7), NASH (n = 8), and healthy controls (n = 9) were studied in vivo. HDL maturation and remodeling, antioxidant, cholesterol efflux properties, and activities of lecithin-cholesterol ester acyltransferase and cholesterol ester transfer protein (CETP) were quantified using in vitro assays. All patients with NAFLD had increased turnover of both HDL cholesterol (HDLc; 0.16 ± 0.09 vs. 0.34 ± 0.18 days, P < 0.05) and apolipoprotein A1 (ApoAI) (0.26 ± 0.04 vs. 0.34 ± 0.06 days, P < 0.005) compared with healthy controls. The fractional catabolic rates of other HDL proteins, including ApoAII (and ApoAIV) were higher (P < 0.05) in patients with NAFLD who also had higher CETP activity, ApoAI/HDLc ratio (P < 0.05). NAFLD-induced alterations were associated with lower antioxidant (114.2 ± 46.6 vs. 220.5 ± 48.2 nmol·mL-1·min-1) but higher total efflux properties of HDL (23.4 ± 1.3% vs. 25.5 ± 2.3%) (both P < 0.05), which was more pronounced in individuals with NASH. However, no differences were observed in either HDL turnover, antioxidant, and cholesterol efflux functions of HDL or HDL proteins' turnover between subjects with SS and subjects with NASH. Thus, HDL metabolism and function are altered in NAFLD without any significant differences between SS and NASH.
Collapse
Affiliation(s)
| | | | | | - Kwangwon Lee
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, Ohio
| | - Abdullah Osme
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, Ohio
| | - Chunki Kim
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, Ohio
| | - Serguei Ilchenko
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, Ohio
| | - Shuhui W Lorkowski
- Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, Ohio
| | - Jonathan D Smith
- Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, Ohio
| | | | - Takhar Kasumov
- Department of Gastroenterology, Cleveland Clinic, Cleveland, Ohio
- Department of Pharmaceutical Sciences, Northeast Ohio Medical University, Rootstown, Ohio
| |
Collapse
|
7
|
Gao D, Podrez EA. Characterization of covalent modifications of HDL apoproteins by endogenous oxidized phospholipids. Free Radic Biol Med 2018; 115:57-67. [PMID: 29155052 PMCID: PMC5767518 DOI: 10.1016/j.freeradbiomed.2017.11.012] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/11/2017] [Accepted: 11/14/2017] [Indexed: 12/31/2022]
Abstract
High density lipoprotein (HDL) is cardioprotective, unless it is pathologically modified under oxidative stress. Covalent modifications of lipid-free apoA-I, the most abundant apoprotein in HDL, compromise its atheroprotective functions. HDL is enriched in oxidized phospholipids (oxPL) in vivo in oxidative stress. Furthermore, oxidized phospholipids can covalently modify HDL apoproteins. We have now carried out a systematic analysis of modifications of HDL apoproteins by endogenous oxPL. Human HDL or plasma were oxidized using a physiologically relevant MPO-H2O2-NO2- system or AIPH, or were exposed to synthetic oxPL. Protein adduction by oxPL was assessed using LC-MS/MS and MALDI-TOF MS. The pattern of HDL apoprotein modification by oxPL was independent of the oxidation systems used. ApoA-I and apoA-II were the major modification targets. OxPL with a γ-hydroxy (or oxo)-alkenal were mostly responsible for modifications, and the Michael adduct was the most abundant adduct. Histidines and lysines in helices 5-8 of apoA-I were highly susceptible to oxPL modifications, while lysines in helices 1, 2, 4 and 10 were resistant to modification by oxPL. In plasma exposed to oxidation or synthetic oxPL, oxPL modification was highly selective, and four histidines (H155, H162, H193 and H199) in helices 6-8 of apoA-I were the main modification target. H710 and H3613 in apoB-100 of LDL and K190 of human serum albumin were also modified by oxPL but to a lesser extent. Comparison of oxPL with short chain aldehyde HNE using MALDI-TOF MS demonstrated high selectivity and efficiency of oxPL in the modification of HDL apoproteins. These findings provide a novel insight into a potential mechanism of the loss of atheroprotective function of HDL in conditions of oxidative stress.
Collapse
Affiliation(s)
- Detao Gao
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, United States
| | - Eugene A Podrez
- Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, United States.
| |
Collapse
|
8
|
Li L, Sawashita J, Ding X, Yang M, Xu Z, Miyahara H, Mori M, Higuchi K. Caloric restriction reduces the systemic progression of mouse AApoAII amyloidosis. PLoS One 2017; 12:e0172402. [PMID: 28225824 PMCID: PMC5321440 DOI: 10.1371/journal.pone.0172402] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Accepted: 11/22/2016] [Indexed: 11/19/2022] Open
Abstract
In mouse senile amyloidosis, apolipoprotein (Apo) A-II is deposited extracellularly in many organs in the form of amyloid fibrils (AApoAII). Reduction of caloric intake, known as caloric restriction (CR), slows the progress of senescence and age-related disorders in mice. In this study, we intravenously injected 1 μg of isolated AApoAII fibrils into R1.P1-Apoa2c mice to induce experimental amyloidosis and investigated the effects of CR for the next 16 weeks. In the CR group, AApoAII amyloid deposits in the liver, tongue, small intestine and skin were significantly reduced compared to those of the ad libitum feeding group. CR treatment led to obvious reduction in body weight, improvement in glucose metabolism and reduction in the plasma concentration of ApoA-II. Our molecular biological analyses of the liver suggested that CR treatment might improve the symptoms of inflammation, the unfolded protein response induced by amyloid deposits and oxidative stress. Furthermore, we suggest that CR treatment might improve mitochondrial functions via the sirtuin 1-peroxisome proliferator-activated receptor γ coactivator 1α (SIRT1-PGC-1α) pathway. We suggest that CR is a promising approach for treating the onset and/or progression of amyloidosis, especially for systemic amyloidosis such as senile AApoAII amyloidosis. Our analysis of CR treatment for amyloidosis should provide useful information for determining the cause of amyloidosis and developing effective preventive treatments.
Collapse
Affiliation(s)
- Lin Li
- Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of Medicine, Matsumoto, Japan
| | - Jinko Sawashita
- Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of Medicine, Matsumoto, Japan
- Department of Biological Sciences for Intractable Neurological Diseases, Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Matsumoto, Japan
- * E-mail:
| | - Xin Ding
- Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of Medicine, Matsumoto, Japan
| | - Mu Yang
- Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of Medicine, Matsumoto, Japan
| | - Zhe Xu
- Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of Medicine, Matsumoto, Japan
| | - Hiroki Miyahara
- Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of Medicine, Matsumoto, Japan
| | - Masayuki Mori
- Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of Medicine, Matsumoto, Japan
- Department of Advanced Medicine for Health Promotion, Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Matsumoto, Japan
| | - Keiichi Higuchi
- Department of Aging Biology, Institute of Pathogenesis and Disease Prevention, Shinshu University Graduate School of Medicine, Matsumoto, Japan
- Department of Biological Sciences for Intractable Neurological Diseases, Institute for Biomedical Sciences, Interdisciplinary Cluster for Cutting Edge Research, Shinshu University, Matsumoto, Japan
| |
Collapse
|
9
|
Li D, Xiong Q, Peng J, Hu B, Li W, Zhu Y, Shen X. Hydrogen Sulfide Up-Regulates the Expression of ATP-Binding Cassette Transporter A1 via Promoting Nuclear Translocation of PPARα. Int J Mol Sci 2016; 17:ijms17050635. [PMID: 27136542 PMCID: PMC4881461 DOI: 10.3390/ijms17050635] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 04/18/2016] [Accepted: 04/20/2016] [Indexed: 12/25/2022] Open
Abstract
ATP binding cassette transporter A1 (ABCA1) plays a key role in atherogenesis. Hydrogen sulfide (H2S), a gasotransmitter, has been reported to play an anti-atherosclerotic role. However, the underlying mechanisms are largely unknown. In this study we examined whether and how H2S regulates ABCA1 expression. The effect of H2S on ABCA1 expression and lipid metabolism were assessed in vitro by cultured human hepatoma cell line HepG2, and in vivo by ApoE−/− mice with a high-cholesterol diet. NaHS (an exogenous H2S donor) treatment significantly increased the expression of ABCA1, ApoA1, and ApoA2 and ameliorated intracellular lipid accumulation in HepG2 cells. Depletion of the endogenous H2S generator cystathionine γ-lyase (CSE) by small RNA interference (siRNA) significantly decreased the expression of ABCA1 and resulted in the accumulation of lipids in HepG2 cells. In vivo NaHS treatment significantly reduced the serum levels of total cholesterol (TC), triglycerides (TG), and low-density lipoproteins (LDL), diminished atherosclerotic plaque size, and increased hepatic ABCA1 expression in fat-fed ApoE−/− mice. Further study revealed that NaHS upregulated ABCA1 expression by promoting peroxisome proliferator-activated receptor α (PPARα) nuclear translocation. H2S up-regulates the expression of ABCA1 by promoting the nuclear translocation of PPARα, providing a fundamental mechanism for the anti-atherogenic activity of H2S. H2S may be a promising potential drug candidate for the treatment of atherosclerosis.
Collapse
Affiliation(s)
- Dong Li
- Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
| | - Qinghui Xiong
- Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201210, China.
- Improvinglife Biological Technology (Shanghai) Co., Ltd., Shanghai 201210, China.
| | - Jin Peng
- Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
| | - Bin Hu
- Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201210, China.
| | - Wanzhen Li
- Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
| | - Yizhun Zhu
- Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201210, China.
| | - Xiaoyan Shen
- Laboratory of Pharmacology and Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
- Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai 201210, China.
| |
Collapse
|
10
|
Vergès B, Adiels M, Boren J, Barrett PH, Watts GF, Chan D, Duvillard L, Söderlund S, Matikainen N, Kahri J, Lundbom N, Lundbom J, Hakkarainen A, Aho S, Simoneau-Robin I, Taskinen MR. ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity. J Clin Endocrinol Metab 2016; 101:1398-406. [PMID: 26835543 DOI: 10.1210/jc.2015-3740] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
We study the associations between apoA-II fractional catabolic rate (FCR) and the kinetics of VLDL subspecies and apoA-I and show that, in abdominally obese individuals, apoA-II FCR is positively and independently associated with both apoA-I FCR and VLDL1-TG indirect FCR.
Collapse
Affiliation(s)
- Bruno Vergès
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Martin Adiels
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Jan Boren
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Peter Hugh Barrett
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Gerald F Watts
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Dick Chan
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Laurence Duvillard
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Sanni Söderlund
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Niina Matikainen
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Juhani Kahri
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Nina Lundbom
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Jesper Lundbom
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Antti Hakkarainen
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Serge Aho
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Isabelle Simoneau-Robin
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| | - Marja-Riitta Taskinen
- Departments of Endocrinology-Diabetology (B.V., I.S.-R.), Medical Biology (L.D.), and Statistics and Epidemiology (S.A.), University Hospital, 21000 Dijon, France; Centre Recherche INSERM 866 (B.V., L.D.), 21079 Dijon, France; Departments of Molecular and Clinical Medicine (M.A., J.B.) and Mathematical Sciences (M.A.), University of Gothenburg, S-405 30 Gothenburg, Sweden; Faculty of Engineering, Computing, and Mathematics (P.H.B.), University of Western Australia, Perth, Western Australia 6872, Australia; Lipid Disorders Clinic (G.F.W., D.C.), Metabolic Research Centre, Department of Cardiovascular Medicine, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6847, Australia; and Heart and Lung Centre (S.S., N.M., M.-R.T.), Helsinki University Hospital and Research Programs' Unit, Department of Diabetes and Obesity, University of Helsinki, Endocrinology, Abdominal Centre (N.M.), Department of Internal Medicine and Rehabilitation (J.K.), and Department of Radiology (N.L., J.L., A.H.), Helsingin ja Uudenmaan Sairaanhoitopiiri Medical Imaging Centre, Helsinki University Hospital, FI-00290 Helsinki, Finland
| |
Collapse
|
11
|
Azizkhanian I, Trenchevska O, Bashawri Y, Hu J, Koska J, Reaven PD, Nelson RW, Nedelkov D, Yassine HN. Posttranslational modifications of apolipoprotein A-II proteoforms in type 2 diabetes. J Clin Lipidol 2016; 10:808-815. [PMID: 27578111 DOI: 10.1016/j.jacl.2016.03.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2015] [Revised: 02/25/2016] [Accepted: 03/01/2016] [Indexed: 01/04/2023]
Abstract
BACKGROUND Apolipoprotein A-II (apoA-II) is the second most abundant protein in high-density lipoprotein particles. However, it exists in plasma in multiple forms. The effect of diabetes on apoA-II proteoforms is not known. OBJECTIVE Our objective was to characterize plasma apoA-II proteoforms in participants with and without type 2 diabetes. METHODS Using a novel mass spectrometric immunoassay, the relative abundance of apoA-II proteoforms was examined in plasma of 30 participants with type 2 diabetes and 25 participants without diabetes. RESULTS Six apoA-II proteoforms (monomer, truncated TQ monomer, truncated Q monomer, dimer, truncated Q dimer, and truncated 2Qs dimer) and their oxidized proteoforms were identified. The ratios of oxidized monomer and all oxidized proteoforms to the native apoA-II were significantly greater in the diabetic group (P = .004 and P = .005, respectively) compared with the nondiabetic group. CONCLUSION The relative abundance of oxidized apoA-II is significantly increased in type 2 diabetes.
Collapse
Affiliation(s)
- Ida Azizkhanian
- Department of Medicine, University of Southern California, Los Angeles, CA, USA
| | | | - Yara Bashawri
- Department of Medicine, University of Southern California, Los Angeles, CA, USA; King Fahad Medical City, Riyadh, Saudi Arabia
| | - Jiaqi Hu
- Department of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Juraj Koska
- Department of Medicine, Phoenix VA Health Care System, Phoenix, AZ, USA
| | - Peter D Reaven
- Department of Medicine, Phoenix VA Health Care System, Phoenix, AZ, USA
| | | | | | - Hussein N Yassine
- Department of Medicine, University of Southern California, Los Angeles, CA, USA.
| |
Collapse
|
12
|
Dietrich MA, Nynca J, Adamek M, Steinhagen D, Karol H, Ciereszko A. Expression of apolipoprotein A-I and A-II in rainbow trout reproductive tract and their possible role in antibacterial defence. Fish Shellfish Immunol 2015; 45:750-756. [PMID: 26044744 DOI: 10.1016/j.fsi.2015.05.048] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Revised: 05/23/2015] [Accepted: 05/29/2015] [Indexed: 06/04/2023]
Abstract
Antimicrobial proteins such as apolipoproteins A (ApoA-I and ApoA-II) play an important role in the primary defence barrier in vertebrates including fish. The aims of the present study were to isolate and characterise rainbow trout seminal plasma ApoA-I and ApoA-II, to examine the mRNA expression of each apolipoprotein in testis and spermatic ducts, and to test the antibacterial properties of the apolipoproteins. Using a three-step isolation procedure consisting of ion-exchange chromatography, gel filtration and preparative SDS-PAGE, apolipoproteins were purified and identified as ApoA-I and ApoA-II. Both apolipoproteins were represented by several proteoforms. The expression of ApoA-I and ApoA-II mRNA in the reproductive tract and their antibacterial properties against Escherichia coli suggest that seminal apolipoproteins play an important role in innate immunity in the rainbow trout reproductive tract. The functions of seminal ApoA can be related to protection of sperm and reproductive tissue from microbial attack and to the maintenance of sperm membrane integrity.
Collapse
Affiliation(s)
- Mariola A Dietrich
- Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn, Department of Gamete and Embryo Biology, Poland.
| | - Joanna Nynca
- Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn, Department of Gamete and Embryo Biology, Poland
| | - Mikołaj Adamek
- University of Veterinary Medicine in Hanover, Fish Disease Research Unit, Germany
| | - Dieter Steinhagen
- University of Veterinary Medicine in Hanover, Fish Disease Research Unit, Germany
| | - Halina Karol
- Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn, Department of Gamete and Embryo Biology, Poland
| | - Andrzej Ciereszko
- Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn, Department of Gamete and Embryo Biology, Poland
| |
Collapse
|
13
|
Ma M, Crump D, Farmahin R, Kennedy SW. Comparing the effects of tetrabromobisphenol-A, bisphenol A, and their potential replacement alternatives, TBBPA-bis(2,3-dibromopropyl ether) and bisphenol S, on cell viability and messenger ribonucleic acid expression in chicken embryonic hepatocytes. Environ Toxicol Chem 2015; 34:391-401. [PMID: 25470364 DOI: 10.1002/etc.2814] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Revised: 11/03/2014] [Accepted: 11/17/2014] [Indexed: 06/04/2023]
Abstract
A market for alternative brominated flame retardants (BFRs) has emerged recently due to the phase out of persistent and inherently toxic BFRs. Several of these replacement compounds have been detected in environmental matrices, including wild birds. A chicken embryonic hepatocyte (CEH) assay was utilized to assess the effects of the BFR, tetrabromobisphenol-A (TBBPA), and its replacement alternative, tetrabromobisphenol A bis(2,3-dibromopropyl ether [TBBPA-DBPE]) on cell viability and messenger ribonucleic acid (mRNA) expression. Bisphenol A (BPA) and 1 of its replacement alternatives, bisphenol S (BPS), were also screened for effects. Both TBBPA and BPA decreased CEH viability with calculated median lethal concentration (LC50) values of 40.6 μM and 61.7 μM, respectively. However, the replacement alternatives, TBBPA-DBPE and BPS, did not affect cell viability (up to 300 μM). Effects on mRNA expression were determined using an Avian ToxChip polymerse chain reaction (PCR) array and a real-time (RT)-PCR assay for the estrogen-responsive genes, apolipoproteinII (ApoII) and vitellogenin (Vtg). A luciferase reporter gene assay was used to assess dioxin-like effects. Tetrabromobisphenol-A altered mRNA levels of 4 genes from multiple toxicity pathways and increased luciferase activity in the luciferase reporter gene assay, whereas its alternative, TBBPA-DBPE, only altered 1 gene on the array, Cyp1a4, and increased luciferase activity. At 300 μM, a concentration that decreased cell viability for TBBPA and BPA, the BPA replacement, BPS, altered the greatest number of transcripts, including both ApoII and Vtg. Bisphenol A exposure did not alter any genes on the array but did up-regulate Vtg at 10 μM. Characterization of the potential toxicological and molecular-level effects of these compounds will ideally be useful to chemical regulators tasked with assessing the risk of new and existing chemicals.
Collapse
Affiliation(s)
- Melissa Ma
- National Wildlife Research Centre, Environment Canada, Ottawa, Ontario, Canada
| | | | | | | |
Collapse
|
14
|
Kanai T, Yamagata T, Ito T, Odaka J, Saito T, Aoyagi J, Momoi MY. Apolipoprotein AII levels are associated with the UP/UCr levels in idiopathic steroid-sensitive nephrotic syndrome. Clin Exp Nephrol 2014; 19:107-13. [PMID: 24633472 DOI: 10.1007/s10157-014-0957-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2013] [Accepted: 02/27/2014] [Indexed: 01/12/2023]
Abstract
BACKGROUND Various humoral factors have been proposed as causal agents of idiopathic steroid-sensitive nephrotic syndrome (ISSNS), resulting in varying data. We used mass spectrometry (MS) to analyze serum proteins in a search for proteins that might be involved in ISSNS pathophysiology. METHODS Serial serum samples were obtained from 33 children with ISSNS. Samples were collected during Phase A1 [the acute phase prior to steroid treatment (STx)], Phase A2 (remission with STx), and Phase A3 (remission without any medication). We also included age- and sex-matched two control groups comprising children with normal urinalysis (Group B) and children with a nephrotic syndrome other than ISSNS (Group C). The urinary protein/urinary creatinine (UP/UCr) ratios were not statistically different between Phase A1 and Group C. Samples were analyzed using surface-enhanced laser desorption/ionization time of flight MS. RESULTS A total of 207 peptide ion peaks were detected in the range of m/z 2000-10000. Four peptide ions (m/z 6444, 6626, 8695, and 8915) were detected at significant elevation during Phase A1 compared with Phase A2, Phase A3, and Group C. The intensities of m/z 6444 and 8695 were higher in Phase A3 than in Group B. There were significant correlations between the intensities of m/z 6626, 8695, and 8915 and UP/UCr levels. The m/z 8695 was identified as apolipoprotein AII. CONCLUSIONS Apolipoprotein AII was detected as a protein associated with the UP/UCr levels in pediatric ISSNS. Our findings present an interesting starting point for further investigation into the pathophysiology of ISSNS.
Collapse
Affiliation(s)
- Takahiro Kanai
- Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji Shimotsuke, Tochigi, 329-0498, Japan,
| | | | | | | | | | | | | |
Collapse
|
15
|
|
16
|
Corsetti JP, Bakker SJL, Sparks CE, Dullaart RPF. Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein. PLoS One 2012; 7:e39110. [PMID: 22723940 PMCID: PMC3377620 DOI: 10.1371/journal.pone.0039110] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2012] [Accepted: 05/17/2012] [Indexed: 11/19/2022] Open
Abstract
Background In a previous report by our group, high levels of apolipoprotein E (apoE) were demonstrated to be associated with risk of incident cardiovascular disease in women with high levels of C-reactive protein (CRP) in the setting of both low (designated as HR1 subjects) and high (designated as HR2 subjects) levels of high-density lipoprotein cholesterol (HDL-C). To assess whether apolipoprotein A-II (apoA-II) plays a role in apoE-associated risk in the two female groups. Methodology/Principal Outcome event mapping, a graphical data exploratory tool; Cox proportional hazards multivariable regression; and curve-fitting modeling were used to examine apoA-II influence on apoE-associated risk focusing on HDL particles with apolipoprotein A-I (apoA-I) without apoA-II (LpA-I) and HDL particles with both apoA-I and apoA-II (LpA-I:A-II). Results of outcome mappings as a function of apoE levels and the ratio of apoA-II to apoA-I revealed within each of the two populations, a high-risk subgroup characterized in each situation by high levels of apoE and additionally: in HR1, by a low value of the apoA-II/apoA-I ratio; and in HR2, by a moderate value of the apoA-II/apoA-I ratio. Furthermore, derived estimates of LpA-I and LpA-I:A-II levels revealed for high-risk versus remaining subjects: in HR1, higher levels of LpA-I and lower levels of LpA-I:A-II; and in HR2 the reverse, lower levels of LpA-I and higher levels of LpA-I:A-II. Results of multivariable risk modeling as a function of LpA-I and LpA-I:A-II (dichotomized as highest quartile versus combined three lower quartiles) revealed association of risk only for high levels of LpA-I:A-II in the HR2 subgroup (hazard ratio 5.31, 95% CI 1.12–25.17, p = 0.036). Furthermore, high LpA-I:A-II levels interacted with high apoE levels in establishing subgroup risk. Conclusions/Significance We conclude that apoA-II plays a significant role in apoE-associated risk of incident CVD in women with high levels of HDL-C and CRP.
Collapse
Affiliation(s)
- James P Corsetti
- Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
| | | | | | | |
Collapse
|
17
|
Chièze L, Bolanos-Garcia VM, Le Caër G, Renault A, Vié V, Beaufils S. Difference in lipid packing sensitivity of exchangeable apolipoproteins apoA-I and apoA-II: an important determinant for their distinctive role in lipid metabolism. Biochim Biophys Acta 2012; 1818:2732-41. [PMID: 22627110 DOI: 10.1016/j.bbamem.2012.05.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/14/2011] [Revised: 05/11/2012] [Accepted: 05/14/2012] [Indexed: 12/21/2022]
Abstract
Exchangeable apolipoproteins A-I and A-II play distinct roles in reverse cholesterol transport. ApoA-I interacts with phospholipids and cholesterol of the cell membrane to make high density lipoprotein particles whereas apolipoprotein A-II interacts with high density lipoprotein particles to release apolipoprotein A-I. The two proteins show a high activity at the aqueous solution/lipid interface and are characterized by a high content of amphipathic α-helices built upon repetition of the same structural motif. We set out to investigate to what extent the number of α-helix repeats of this structural motif modulates the affinity of the protein for lipids and the sensitivity to lipid packing. To this aim we have compared the insertion of apolipoproteins A-I and A-II in phospholipid monolayers formed on a Langmuir trough in conditions where lipid packing, surface pressure and charge were controlled. We also used atomic force microscopy to obtain high resolution topographic images of the surface at a resolution of several nanometers and performed statistical image analysis to calculate the spatial distribution and geometrical shape of apolipoproteins A-I and A-II clusters. Our data indicate that apolipoprotein A-I is sensitive to packing of zwitterionic lipids but insensitive to the packing of negatively charged lipids. Interestingly, apolipoprotein A-II proved to be insensitive to the packing of zwitterionic lipids. The different sensitivity to lipid packing provides clues as to why apolipoprotein A-II barely forms nascent high density lipoprotein particles while apolipoprotein A-I promotes their formation. We conclude that the different interfacial behaviors of apolipoprotein A-I and apolipoprotein A-II in lipidic monolayers are important determinants of their distinctive roles in lipid metabolism.
Collapse
Affiliation(s)
- Lionel Chièze
- Institut de Physique de Rennes, UMR-CNRS 6251 Université de Rennes 1, Campus de Beaulieu, Rennes cedex, France
| | | | | | | | | | | |
Collapse
|
18
|
Kameda T, Usami Y, Shimada S, Haraguchi G, Matsuda K, Sugano M, Kurihara Y, Isobe M, Tozuka M. Determination of myeloperoxidase-induced apoAI-apoAII heterodimers in high-density lipoprotein. Ann Clin Lab Sci 2012; 42:384-391. [PMID: 23090734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Myeloperoxidase secreted by macrophages and neutrophils in atherosclerotic lesions generates a tyrosyl radical in apolipoprotein (apo) AI, a major protein component of high-density lipoprotein (HDL), thus inducing the formation of apoAI-apoAII heterodimers. It can also cause nitration and chlorination of tyrosine residues. Determining the apoAI-apoAII heterodimer could provide useful information as to functional changes in HDL and/or the progression of atherosclerotic lesions. To this end, the apoAI-apoAII heterodimer was identified in normal human serum by immunoblotting; the band intensity was increased by treatment with myeloperoxidase. This apparent increase in heterodimer formation was quantitatively confirmed by ELISA. In normal human serum, a significant correlation between the concentrations of apoAI-apoAII heterodimer and free apoAII (r=0.763), but not free apoAI (r=0.093), was observed, indicating that heterodimer formation is likely induced on HDL particles carrying both apoAI and apoAII (Lp-AI/AII). In preliminary studies, the levels of apoAI-apoAII heterodimer were statistically higher in plasma from subjects with acute myocardial infarction (AMI) as compared to controls. These findings indicate the possibility that the apoAI-apoAII heterodimer, including nitration and chlorination modifications, may serve as an indicator of atherosclerotic lesions.
Collapse
Affiliation(s)
- Takahiro Kameda
- Analytical Laboratory Chemistry, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Wróblewska M. The origin and metabolism of a nascent pre-β high density lipoprotein involved in cellular cholesterol efflux. Acta Biochim Pol 2011; 58:275-285. [PMID: 21750785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2010] [Revised: 03/25/2011] [Accepted: 07/01/2011] [Indexed: 05/31/2023]
Abstract
The pre-β HDL fraction constitutes a heterogeneous population of discoid nascent HDL particles. They transport from 1 to 25 % of total human plasma apo A-I. Pre-β HDL particles are generated de novo by interaction between ABCA1 transporters and monomolecular lipid-free apo A-I. Most probably, the binding of apo A-I to ABCA1 initiates the generation of the phospholipid-apo A-I complex which induces free cholesterol efflux. The lipid-poor nascent pre-β HDL particle associates with more lipids through exposure to the ABCG1 transporter and apo M. The maturation of pre-β HDL into the spherical α-HDL containing apo A-I is mediated by LCAT, which esterifies free cholesterol and thereby forms a hydrophobic core of the lipoprotein particle. LCAT is also a key factor in promoting the formation of the HDL particle containing apo A-I and apo A-II by fusion of the spherical α-HDL containing apo A-I and the nascent discoid HDL containing apo A-II. The plasma remodelling of mature HDL particles by lipid transfer proteins and hepatic lipase causes the dissociation of lipid-free/lipid-poor apo A-I, which can either interact with ABCA1 transporters and be incorporated back into pre-existing HDL particles, or eventually be catabolized in the kidney. The formation of pre-β HDL and the cycling of apo A-I between the pre-β and α-HDL particles are thought to be crucial mechanisms of reverse cholesterol transport and the expression of ABCA1 in macrophages may play a main role in the protection against atherosclerosis.
Collapse
|
20
|
Okada T, Yonezawa R, Miyashita M, Mugishima H. Triglyceride concentrations in very low-density lipoprotein fraction in cord blood during 32-35 week gestation. Early Hum Dev 2011; 87:451. [PMID: 21482048 DOI: 10.1016/j.earlhumdev.2011.03.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2011] [Revised: 03/19/2011] [Accepted: 03/22/2011] [Indexed: 11/28/2022]
|
21
|
Getz GS, Reardon CA. High-density lipoprotein function in regulating insulin secretion: possible relevance to metabolic syndrome. Arterioscler Thromb Vasc Biol 2010; 30:1497-9. [PMID: 20631346 DOI: 10.1161/atvbaha.110.210583] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
Qian J, Yan J, Ge F, Zhang B, Fu X, Tomozawa H, Sawashita J, Mori M, Higuchi K. Mouse senile amyloid fibrils deposited in skeletal muscle exhibit amyloidosis-enhancing activity. PLoS Pathog 2010; 6:e1000914. [PMID: 20502680 PMCID: PMC2873911 DOI: 10.1371/journal.ppat.1000914] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2009] [Accepted: 04/20/2010] [Indexed: 11/18/2022] Open
Abstract
Amyloidosis describes a group of protein folding diseases in which amyloid proteins are abnormally deposited in organs and/or tissues as fine fibrils. Mouse senile amyloidosis is a disorder in which apolipoprotein A-II (apoA-II) deposits as amyloid fibrils (AApoAII) and can be transmitted from one animal to another both by the feces and milk excreted by mice with amyloidosis. Thus, mouse AApoAII amyloidosis has been demonstrated to be a “transmissible disease”. In this study, to further characterize the transmissibility of amyloidosis, AApoAII amyloid fibrils were injected into transgenic Apoa2cTg+/− and normal R1.P1-Apoa2c mice to induce AApoAII systemic amyloidosis. Two months later, AApoAII amyloid deposits were found in the skeletal muscles of amyloid-affected mice, primarily in the blood vessels and in the interstitial tissues surrounding muscle fibers. When amyloid fibrils extracted from the skeletal muscles were subjected to Western blot analysis, apoA-II was detected. Amyloid fibril fractions isolated from the muscles not only demonstrated the structure of amyloid fibrils but could also induce amyloidosis in young mice depending on its fibril conformation. These findings present a possible pathogenesis of amyloidosis: transmission of amyloid fibril conformation through muscle, and shed new light on the etiology involved in amyloid disorders. “Amyloidosis”, a group of protein folding diseases characterized by deposition of fine fibrils in tissues, is a common disorder of protein metabolism and can be acquired, inherited and/or age-associated. Recently, prion-like transmission has been found in various amyloidoses. AApoAII amyloid fibrils in mouse senile amyloidosis have exhibited transmissibility. For instance, ingested AApoAII amyloid fibrils, which were excreted from mice and contained in feces or milk, function as seeds for changing apoA-II amyloid precursor protein to the fibrillar form and cause mouse senile amyloidosis. However, transmissibility through other pathways has not yet been established. Here, we induced AApoAII systemic amyloidosis in transgenic Apoa2cTg+/− and normal R1.P1-Apoa2c mice to analyze the transmissibility of mouse senile amyloidosis through muscle tissues. In this study, we not only detected AApoAII deposited in various skeletal muscles, but also found that it could induce secondary transmission of AApoAII amyloidosis. This is the first evidence of transmission through skeletal muscles in non-prion systemic amyloidosis. This pathway of transmission provides new insight into the potential for food-borne pathogenesis and etiology of systemic amyloidosis.
Collapse
Affiliation(s)
- Jinze Qian
- Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
- Department of Pathology, Hebei Medical University, Shijiazhuang, China
| | - Jingmin Yan
- Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
| | - Fengxia Ge
- Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
| | - Beiru Zhang
- Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
| | - Xiaoying Fu
- Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
| | - Hiroshi Tomozawa
- Division of Laboratory Animal Research, Research Center for Human and Environmental Science, Shinshu University, Matsumoto, Japan
| | - Jinko Sawashita
- Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
| | - Masayuki Mori
- Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
| | - Keiichi Higuchi
- Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Japan
- * E-mail:
| |
Collapse
|
23
|
Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, Rye KA. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 2010; 30:1642-8. [PMID: 20466975 DOI: 10.1161/atvbaha.110.207373] [Citation(s) in RCA: 207] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
OBJECTIVE Type 2 diabetes is characterized by impaired beta-cell secretory function, insulin resistance, reduced high-density lipoprotein (HDL) levels, and increased cardiovascular risk. Given the current interest in therapeutic interventions that raise HDLs levels, this study investigates the effects of HDLs on insulin secretion from beta-cells. METHODS AND RESULTS Incubation of Min6 cells and primary islets under basal or high-glucose conditions with either apolipoprotein (apo) A-I or apoA-II in the lipid-free form, as a constituent of discoidal reconstituted HDLs (rHDLs), or with HDLs isolated from human plasma increased insulin secretion up to 5-fold in a calcium-dependent manner. The increase was time and concentration dependent. It was also K(ATP) channel and glucose metabolism dependent under high-glucose, but not low-glucose, conditions. The lipid-free apolipoprotein-mediated increase in insulin secretion was ATP binding cassette (ABC) transporter A1 and scavenger receptor-B1 dependent. The rHDL-mediated increase in insulin secretion was ABCG1 dependent. Exposure of beta-cells to lipid-free apolipoproteins also increased insulin mRNA expression and insulin secretion without significantly depleting intracellular insulin or cholesterol levels. CONCLUSIONS These results establish that lipid-free and lipid-associated apoA-I and apoA-II increase beta-cell insulin secretion and indicate that interventions that raise HDLs levels may be beneficial in type 2 diabetes.
Collapse
|
24
|
Puppione DL, Della Donna L, Laganowsky AD, Bassilian S, Souda P, Ryder OA, Whitelegge JP. Mass spectral analyses of the two major apolipoproteins of great ape high density lipoproteins. Comp Biochem Physiol Part D Genomics Proteomics 2009; 4:305-309. [PMID: 21298813 PMCID: PMC2776726 DOI: 10.1016/j.cbd.2009.09.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
The two major apolipoproteins associated with human and chimpanzee (Pan troglodytes) high density lipoproteins (HDL) are apoA-I and dimeric apoA-II. Although humans are closely related to great apes, apolipoprotein data do not exist for bonobos (Pan paniscus), western lowland gorillas (Gorilla gorilla gorilla) and the Sumatran orangutans (Pongo abelii). In the absence of any data, other great apes simply have been assumed to have dimeric apoA-II while other primates and most other mammals have been shown to have monomeric apoA-II. Using mass spectrometry, we have measured the molecular masses of apoA-I and apoA-II associated with the HDL of these great apes. Each was observed to have dimeric apoA-II. Being phylogenetically related, one would anticipate these apolipoproteins having a high percentage of invariant sequences when compared with human apolipoproteins. However, the orangutan, which diverged from the human lineage between 16 and 21 million years ago, had an apoA-II with the lowest monomeric mass, 8031.3 Da and the highest apoA-I value, 28,311.7 Da, currently reported for various mammals. Interestingly, the gorilla that diverged from the lineage leading to the human–chimpanzee branch after the orangutan had almost identical mass values to those reported for human apoA-I and apoA-II. But chimpanzee and the bonobo that diverged more recently had identical apoA-II mass values that were slightly larger than reported for the human apolipoprotein. The chimpanzee A-I mass values were very close to those of humans; however, the bonobo had values intermediate to the molecular masses of orangutan and the other great apes. With the already existing genomic data for chimpanzee and the recent entries for the orangutan and gorilla, we were able to demonstrate a close agreement between our mass spectral data and the calculated molecular weights determined from the predicted primary sequences of the respective apolipoproteins. Post-translational modification of these apolipoproteins, involving truncation and oxidation of methionine, are also reported.
Collapse
Affiliation(s)
| | - Lorenza Della Donna
- The Pasarow Mass Spectrometry Laboratory, The Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Arthur D Laganowsky
- The Molecular Biology Institute, USA; The Pasarow Mass Spectrometry Laboratory, The Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Sara Bassilian
- The Pasarow Mass Spectrometry Laboratory, The Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Puneet Souda
- The Pasarow Mass Spectrometry Laboratory, The Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| | - Oliver A Ryder
- San Diego Zoo's Institute for Conservation Research, Escondido, CA 92027, USA
| | - Julian P Whitelegge
- The Molecular Biology Institute, USA; The Pasarow Mass Spectrometry Laboratory, The Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
| |
Collapse
|
25
|
Abstract
A sex difference in surfactant lipids is associated with a higher incidence of respiratory distress syndrome for males in cases of preterm birth. In animal models, the sex difference in surfactant lipids was shown to be androgen receptor-dependent. This report examines expression of apolipoprotein (apo)A-I, apoA-II, apoC-II, apoE, apoH, and lipoprotein lipase (LPL) by quantitative real-time PCR in pools of male and female fetal lung tissues from various mouse litters from gestation day (GD) 15.5 to 18.5, and in various adult tissues. Although the expression profiles of ApoA-I, ApoA-II, ApoC-II, and ApoH are complex, these genes are co-regulated and they all present a sex difference (P=0.0896, 0.0896, 0.0195, and 0.0607 respectively) with higher expression for females for several litters. Pulmonary expression of apoA-I, apoA-II, and apoH were specific to the developing lung. ApoE and LPL mRNAs showed a significant increase from GD 17.5 to 18.5. An increase in apoA-I-, apoA-II-, apoC-II-, and apoH-mRNA accumulation was observed from GD 16.5 to 17.5 in correlation with the emergence of mature type II pneumonocytes. These four apolipoprotein genes are co-regulated with type 2 and 5 17beta-hydroxysteroid dehydrogenases, which are respectively involved in inactivation and synthesis of androgens. Finally, apoC-II was detected by immunohistochemistry in epithelial cells of the distal epithelium. Positive signals looking like secretory granules were located near the basal membrane. Our results are compatible with a role for apolipoproteins in lipid metabolism and transport in the developing lung in association with the sex difference in surfactant lipid synthesis.
Collapse
Affiliation(s)
- Pierre R Provost
- Laboratory of Ontogeny and Reproduction, Centre Hospitalier Universitaire de Québec, Pavillon CHUL, Québec, Canada
| | | | | |
Collapse
|
26
|
Wróblewska M. [The role of apolipoproteins A-I and A-II in plasma HDL remodeling]. Postepy Biochem 2009; 55:315-322. [PMID: 19928588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Apolipoprotein (apo) A-I is a key HDL protein participating in the process of reverse cholesterol transport. A small part of plasma apo A-I exists as free protein which is a substrate for generation of discoid HDL precursors, containing small amounts of phospholipids and free cholesterol. The cycling of apo A-I between precursor and mature forms of HDL is an essential element of HDL remodeling in plasma. The second most abundant protein of human HDL is apo A-II, nevertheless, it is present only in about half of the HDL particles in plasma. The mechanism mediating the formation of HDL containing apo A-I and apo A-II is unknown. The role of apo A-II in reverse cholesterol transport generates controversy. Different observations indicate either proatherogenic or proinflammatory properties of apo A-II. Also the participation of apo A-II in plasma HDL remodeling remains unclear. Apo A-II maybe a factor stabilizing HDL particles. This protein may also take part in regulation of VLDL metabolism. The review presents current knowledge concerning participation of apo A-I and apo A-II in plasma HDL remodeling.
Collapse
Affiliation(s)
- Małgorzata Wróblewska
- Department of Laboratory Medicine, Medical University of Gdańsk, 7 Debinki St., 80-211 Gdańsk, Poland.
| |
Collapse
|
27
|
Thulin P, Glinghammar B, Skogsberg J, Lundell K, Ehrenborg E. PPARdelta increases expression of the human apolipoprotein A-II gene in human liver cells. Int J Mol Med 2008; 21:819-824. [PMID: 18506377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023] Open
Abstract
The peroxisome proliferator-activated receptor delta (PPARdelta) is a transcription factor that regulates genes of importance in lipid and glucose metabolism. ApoA-II is one of the major proteins of the HDL-particle. The aim of this study was to investigate the regulation of apoA-II gene expression by PPARdelta. Treatment of HepG2 cells with the PPARdelta specific agonist GW501516 increased apoA-II mRNA expression. Likewise, reporter gene assays using a construct containing 2.7 kb of the proximal apoA-II promoter showed increased activity after treatment with GW501516, both in HepG2 and in HuH-7 cells. Mutation of two putative PPAR response elements (PPREs) in this region showed that the PPRE at position -737/-717 is the functional site. Binding of PPARdelta to this site was confirmed by chromatin immunoprecipitation and gel retardation analyses. In conclusion, PPARdelta increases the expression of the human apoA-II gene in liver cells via a PPRE in the proximal promoter.
Collapse
Affiliation(s)
- Petra Thulin
- Atherosclerosis Research Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
| | | | | | | | | |
Collapse
|
28
|
Mendes AM, Schlegelmilch T, Cohuet A, Awono-Ambene P, De Iorio M, Fontenille D, Morlais I, Christophides GK, Kafatos FC, Vlachou D. Conserved mosquito/parasite interactions affect development of Plasmodium falciparum in Africa. PLoS Pathog 2008; 4:e1000069. [PMID: 18483558 PMCID: PMC2373770 DOI: 10.1371/journal.ppat.1000069] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2007] [Accepted: 04/14/2008] [Indexed: 12/16/2022] Open
Abstract
In much of sub-Saharan Africa, the mosquito Anopheles gambiae is the main vector of the major human malaria parasite, Plasmodium falciparum. Convenient laboratory studies have identified mosquito genes that affect positively or negatively the developmental cycle of the model rodent parasite, P. berghei. Here, we use transcription profiling and reverse genetics to explore whether five disparate mosquito gene regulators of P. berghei development are also pertinent to A. gambiae/P. falciparum interactions in semi-natural conditions, using field isolates of this parasite and geographically related mosquitoes. We detected broadly similar albeit not identical transcriptional responses of these genes to the two parasite species. Gene silencing established that two genes affect similarly both parasites: infections are hindered by the intracellular local activator of actin cytoskeleton dynamics, WASP, but promoted by the hemolymph lipid transporter, ApoII/I. Since P. berghei is not a natural parasite of A. gambiae, these data suggest that the effects of these genes have not been drastically altered by constant interaction and co-evolution of A. gambiae and P. falciparum; this conclusion allowed us to investigate further the mode of action of these two genes in the laboratory model system using a suite of genetic tools and infection assays. We showed that both genes act at the level of midgut invasion during the parasite's developmental transition from ookinete to oocyst. ApoII/I also affects the early stages of oocyst development. These are the first mosquito genes whose significant effects on P. falciparum field isolates have been established by direct experimentation. Importantly, they validate for semi-field human malaria transmission the concept of parasite antagonists and agonists. Malaria is a parasitic infectious disease transmitted by mosquitoes. It impacts half the population of the world and kills 1 to 3 million people every year, the vast majority of whom are children aged below 5 in sub-Saharan Africa. There, the deadliest parasite is Plasmodium falciparum and its most important vector is the mosquito Anopheles gambiae. This study identifies for the first time specific A. gambiae genes that demonstrably regulate the density of mosquito infection by P. falciparum parasites circulating in malaria patients in Africa. These genes function in mosquito lipid transport and intracellular actin cytoskeleton dynamics, and act as an agonist and an antagonist, respectively, of the parasite ookinete-to-oocyst developmental transition. Importantly, our study validates for P. falciparum the concept of mosquito genes that support or hinder parasite development, a concept that we defined previously using a laboratory model system. Thus, the work constitutes a major contribution to understanding meaningful mosquito/parasite interactions in natural transmission conditions.
Collapse
Affiliation(s)
- Antonio M. Mendes
- Imperial College London, Division of Cell and Molecular Biology, Faculty of Natural Sciences, South Kensington Campus, London, United Kingdom
| | - Timm Schlegelmilch
- Imperial College London, Division of Cell and Molecular Biology, Faculty of Natural Sciences, South Kensington Campus, London, United Kingdom
| | - Anna Cohuet
- Institut de Recherche pour le Développement - Laboratoire de Lutte contre les Insectes Nuisibles, UR 016, BP 64501, Montpellier, France
| | - Parfait Awono-Ambene
- Organisation de Coordination de la lutte contre les Endémies en Afrique Centrale, Laboratoire de Recherche sur le Paludisme, BP 288, Yaoundé, Cameroon
| | - Maria De Iorio
- Imperial College London, Division of Epidemiology, Department of Public Health and Primary Care, Faculty of Medicine, St Mary's Campus, London, United Kingdom
| | - Didier Fontenille
- Institut de Recherche pour le Développement - Laboratoire de Lutte contre les Insectes Nuisibles, UR 016, BP 64501, Montpellier, France
| | - Isabelle Morlais
- Organisation de Coordination de la lutte contre les Endémies en Afrique Centrale, Laboratoire de Recherche sur le Paludisme, BP 288, Yaoundé, Cameroon
| | - George K. Christophides
- Imperial College London, Division of Cell and Molecular Biology, Faculty of Natural Sciences, South Kensington Campus, London, United Kingdom
| | - Fotis C. Kafatos
- Imperial College London, Division of Cell and Molecular Biology, Faculty of Natural Sciences, South Kensington Campus, London, United Kingdom
- * E-mail: (FCK); (DV)
| | - Dina Vlachou
- Imperial College London, Division of Cell and Molecular Biology, Faculty of Natural Sciences, South Kensington Campus, London, United Kingdom
- * E-mail: (FCK); (DV)
| |
Collapse
|
29
|
Eichinger A, Nasreen A, Kim HJ, Skerra A. Structural Insight into the Dual Ligand Specificity and Mode of High Density Lipoprotein Association of Apolipoprotein D. J Biol Chem 2007; 282:31068-75. [PMID: 17699160 DOI: 10.1074/jbc.m703552200] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Human apolipoprotein D (ApoD) occurs in plasma associated with high density lipoprotein. Apart from the involvement in lipid metabolism, its binding activity for progesterone and arachidonic acid plays a role in cancer development and neurological diseases. The crystal structures of free ApoD and its complex with progesterone were determined at 1.8A resolution and reveal a lipocalin fold. The narrow, mainly uncharged pocket within the typical beta-barrel accommodates progesterone with its acetyl side chain oriented toward the bottom. The cavity adopts essentially the same shape in the absence of progesterone and allows complexation of arachidonic acid as another cognate ligand. Three of the four extended loops at the open end of the beta-barrel expose hydrophobic side chains, which is an unusual feature for lipocalins and probably effects association with the high density lipoprotein particle by mediating insertion into the lipid phase. This mechanism is in line with an unpaired Cys residue in the same surface region that can form a disulfide cross-link with apolipoprotein A-II.
Collapse
Affiliation(s)
- Andreas Eichinger
- Lehrstuhl für Biologische Chemie, Technische Universität München, 85350 Freising-Weihenstephan, Germany
| | | | | | | |
Collapse
|
30
|
Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler Thromb Vasc Biol 2007; 27:2428-34. [PMID: 17872455 DOI: 10.1161/atvbaha.107.150193] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Pioglitazone, an antihyperglycemic drug, increases plasma high-density lipoprotein (HDL)-cholesterol in patients with type 2 diabetes. The mechanisms by which pioglitazone regulate HDL levels are not clear. This study examined the effect of pioglitazone on hepatocyte apolipoprotein AI (apoA-I) and apoA-II production and HDL-protein/cholesterol ester uptake. METHODS AND RESULTS In human hepatoblastoma (HepG2) cells, pioglitazone, dose-dependently (0.5 to 10 micromol/L), increased the de novo synthesis (up to 45%), secretion (up to 44%), and mRNA expression (up to 59%) of apoA-I. Pioglitazone also increased apoA-II de novo synthesis (up to 73%) and mRNA expression (up to 129%). Pioglitazone did not affect the uptake of HDL3-protein or HDL3-cholesterol ester in HepG2 cells. The pioglitazone-induced apoA-I lipoprotein particles increased cholesterol efflux from THP-1 macrophages. The pioglitazone-induced apoA-I secretion or mRNA expression by the HepG2 cells was abrogated with the suppression of PPAR-alpha by small interfering RNA or a specific inhibitor of PPAR-alpha, MK886. CONCLUSIONS The data indicate that pioglitazone increases HDL by stimulating the de novo hepatic synthesis of apoA-I without affecting hepatic HDL-protein or HDL-cholesterol removal. We suggest that pioglitazone-mediated hepatic activation of PPAR-alpha may be one of the mechanisms of action of pioglitazone to raise hepatic apoA-I and HDL.
Collapse
Affiliation(s)
- Shucun Qin
- Atherosclerosis Research Center, Department of Veterans Affairs Healthcare System, Long Beach, California 90822, USA
| | | | | | | |
Collapse
|
31
|
Yan J, Fu X, Ge F, Zhang B, Yao J, Zhang H, Qian J, Tomozawa H, Naiki H, Sawashita J, Mori M, Higuchi K. Cross-seeding and cross-competition in mouse apolipoprotein A-II amyloid fibrils and protein A amyloid fibrils. Am J Pathol 2007; 171:172-80. [PMID: 17591964 PMCID: PMC1941612 DOI: 10.2353/ajpath.2007.060576] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Murine senile [apolipoprotein A-II amyloid (AApoAII)] and reactive [protein A amyloid (AA)] amyloidosis are reported to be transmissible diseases via a seeding mechanism similar to that observed in the prion-associated disorders, although de novo amyloidogenesis and the progression of AApoAII or AA amyloidosis remain unclear. We examined the effect of co-injection of AApoAII and AA fibrils and multiple inflammatory stimuli in R1.P1-Apoa2(c) mice with the amyloidogenic Apoa2(c) allele. Both AApoAII and AA amyloidosis could be induced in this system, but the two types of amyloid fibrils preferentially promote the formation of the same type of fibrils while inhibiting the formation of the other. Furthermore, we demonstrate that AA or AApoAII amyloidosis could be cross-seeded by predeposited AApoAII or AA fibrils and that the predeposited amyloid fibrils were degraded when the fibril formation was reduced or stopped. In addition, a large proportion of the two amyloid fibrils colocalized during the formation of new fibrils in the spleen and liver. Thus, we propose that AApoAII and AA can both cross-seed and cross-compete with regard to amyloid formation, depending on the stage of amyloidogenesis. These results will aid in the clarification of the mechanisms of pathogenesis and progression of amyloid disorders.
Collapse
Affiliation(s)
- Jingmin Yan
- Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto, Japan
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Dugué-Pujol S, Rousset X, Château D, Pastier D, Klein C, Demeurie J, Cywiner-Golenzer C, Chabert M, Verroust P, Chambaz J, Châtelet FP, Kalopissis AD. Apolipoprotein A-II is catabolized in the kidney as a function of its plasma concentration. J Lipid Res 2007; 48:2151-61. [PMID: 17652309 DOI: 10.1194/jlr.m700089-jlr200] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We investigated in vivo catabolism of apolipoprotein A-II (apo A-II), a major determinant of plasma HDL levels. Like apoA-I, murine apoA-II (mapoA-II) and human apoA-II (hapoA-II) were reabsorbed in the first segment of kidney proximal tubules of control and hapoA-II-transgenic mice, respectively. ApoA-II colocalized in brush border membranes with cubilin and megalin (the apoA-I receptor and coreceptor, respectively), with mapoA-I in intracellular vesicles of tubular epithelial cells, and was targeted to lysosomes, suggestive of degradation. By use of three transgenic lines with plasma hapoA-II concentrations ranging from normal to three times higher, we established an association between plasma concentration and renal catabolism of hapoA-II. HapoA-II was rapidly internalized in yolk sac epithelial cells expressing high levels of cubilin and megalin, colocalized with cubilin and megalin on the cell surface, and effectively competed with apoA-I for uptake, which was inhibitable by anti-cubilin antibodies. Kidney cortical cells that only express megalin internalized LDL but not apoA-II, apoA-I, or HDL, suggesting that megalin is not an apoA-II receptor. We show that apoA-II is efficiently reabsorbed in kidney proximal tubules in relation to its plasma concentration.
Collapse
Affiliation(s)
- Sonia Dugué-Pujol
- Institut National de la Santé et de la Recherche Médicale, U872, Equipe 6, Paris, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Suto JI. Quantitative trait locus analysis of plasma cholesterol levels and body weight by controlling the effects of the Apoa2 allele in mice. J Vet Med Sci 2007; 69:385-92. [PMID: 17485926 DOI: 10.1292/jvms.69.385] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Colleagues and I previously performed quantitative trait locus (QTL) analysis on plasma total-cholesterol (T-CHO) levels in C57BL/6J (B6) x RR F2 mice. We identified only one significant QTL (Cq6) on chromosome 1 in a region containing the Apoa2 gene locus, a convincing candidate gene for Cq6. Because Cq6 was a highly significant QTL, we considered that the detection of other potential QTLs might be hindered. In the present study, QTL analysis was performed in B6.KK-Apoa2b N(8) x RR F2 mice [B6.KK-Apoa2b N(8) is a partial congenic strain carrying the Apoa2b allele from the KK strain, and RR also has the Apoa2b allele] by controlling of the effects of the Apoa2 allele, for identifying additional QTLs. Although no significant QTLs were identified, 2 suggestive QTLs were found on chromosomes 2 and 3 in place of the effects of the Apoa2 allele. A significant body weight QTL was identified on chromosome 3 (Bwq7, peak LOD score 5.2); its effect on body weight was not significant in previously analyzed B6 x RR F2 mice. Suggestive body weight QTL that had been identified in B6 x RR F2 mice on chromosome 4 (LOD score 3.8) was not identified in B6.KK-Apoa2b N(8) x RR F2 mice. Thus, contrary to expectation, the genetic control of body weight was also altered significantly by controlling of the effects of the Apoa2 allele. The QTL mapping strategy by controlling of the effects of a major QTL facilitated the identification of additional QTLs.
Collapse
Affiliation(s)
- Jun-ichi Suto
- Division of Animal Sciences, National Institute of Agrobiological Sciences, Tsukuba, Ibaraki, Japan
| |
Collapse
|
34
|
Ng VY, Huang Y, Reddy LM, Falck JR, Lin ET, Kroetz DL. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha. Drug Metab Dispos 2007; 35:1126-34. [PMID: 17431031 DOI: 10.1124/dmd.106.013839] [Citation(s) in RCA: 119] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Cytochrome P450 (P450) eicosanoids regulate vascular tone, renal tubular transport, cellular proliferation, and inflammation. Both the CYP4A omega-hydroxylases, which catalyze 20-hydroxyeicosatetraenoic acid (20-HETE) formation, and soluble epoxide hydrolase (sEH), which catalyzes epoxyeicosatrienoic acid (EET) degradation to the dihydroxyeicosatrienoic acids (DHETs), are induced upon activation of peroxisome proliferator-activated receptor alpha (PPARalpha) by fatty acids and fibrates. In contrast, the CYP2C epoxygenases, which are responsible for EET formation, are repressed after fibrate treatment. We show here that P450 eicosanoids can bind to and activate PPARalpha and result in the modulation of PPARalpha target gene expression. In transactivation assays, 14,15-DHET, 11,2-EET, and 20-HETE were potent activators of PPARalpha. Gel shift assays showed that EETs, DHETs, and 20-HETE induced PPARalpha-specific binding to its cognate response element. Expression of apolipoprotein A-I was decreased 70% by 20-HETE, whereas apolipoprotein A-II expression was increased up to 3-fold by 11,12-EET, 14,15-DHET, and 20-HETE. In addition, P450 eicosanoids induced CYP4A1, sEH, and CYP2C11 expression, suggesting that they can regulate their own levels. Given that P450 eicosanoids have multiple cardiovascular effects, pharmacological modulation of their formation and/or degradation may yield therapeutic benefits.
Collapse
Affiliation(s)
- Valerie Y Ng
- Department of Biopharmaceutical Sciences, University of California San Francisco, San Francisco, CA 94143-2911, USA
| | | | | | | | | | | |
Collapse
|
35
|
Silva RAGD, Schneeweis LA, Krishnan SC, Zhang X, Axelsen PH, Davidson WS. The structure of apolipoprotein A-II in discoidal high density lipoproteins. J Biol Chem 2007; 282:9713-9721. [PMID: 17264082 DOI: 10.1074/jbc.m610380200] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
It is well accepted that high levels of high density lipoproteins (HDL) reduce the risk of atherosclerosis in humans. Apolipoprotein A-I (apoA-I) and apoA-II are the first and second most common protein constituents of HDL. Unlike apoA-I, detailed structural models for apoA-II in HDL are not available. Here, we present a structural model of apoA-II in reconstituted HDL (rHDL) based on two well established experimental approaches: chemical cross-linking/mass spectrometry (MS) and internal reflection infrared spectroscopy. Homogeneous apoA-II rHDL were reacted with a cross-linking agent to link proximal lysine residues. Upon tryptic digestion, cross-linked peptides were identified by electrospray mass spectrometry. 14 cross-links were identified and confirmed by tandem mass spectrometry (MS/MS). Infrared spectroscopy indicated a beltlike molecular arrangement for apoA-II in which the protein helices wrap around the lipid bilayer rHDL disc. The cross-links were then evaluated on three potential belt arrangements. The data clearly refute a parallel model but support two antiparallel models, especially a "double hairpin" form. These models form the basis for understanding apoA-II structure in more complex HDL particles.
Collapse
Affiliation(s)
- R A Gangani D Silva
- Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio 45237
| | - Lumelle A Schneeweis
- Departments of Pharmacology, Biochemistry, and Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania 19104
| | - Srinivasan C Krishnan
- Mass Spectrometry Application Laboratory, Applied Biosystems, Framingham, Massachusetts 01701
| | - Xiuqi Zhang
- Department of Chemistry, University of Illinois, Chicago, Illinois 60607
| | - Paul H Axelsen
- Departments of Pharmacology, Biochemistry, and Biophysics, University of Pennsylvania, Philadelphia, Pennsylvania 19104
| | - W Sean Davidson
- Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, Ohio 45237.
| |
Collapse
|
36
|
Broedl UC, Jin W, Fuki IV, Millar JS, Rader DJ. Endothelial lipase is less effective at influencing HDL metabolism in vivo in mice expressing apoA-II. J Lipid Res 2006; 47:2191-7. [PMID: 16877778 DOI: 10.1194/jlr.m600036-jlr200] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Endothelial lipase (EL) plays an important physiological role in modulating HDL metabolism. Data suggest that plasma contains an inhibitor of EL, and previous studies have suggested that apolipoprotein A-II (apoA-II) inhibits the activity of several enzymes involved in HDL metabolism. Therefore, we hypothesized that apoA-II may reduce the ability of EL to influence HDL metabolism. To test this hypothesis, we determined the effect of EL expression on plasma phospholipase activity and HDL metabolism in human apoA-I and human apoA-I/A-II transgenic mice. Expression of EL in vivo resulted in lower plasma phospholipase activity and significantly less reduction of HDL-cholesterol, phospholipid, and apoA-I levels in apoA-I/A-II double transgenic mice compared with apoA-I single transgenic mice. We conclude that the presence of apoA-II on HDL particles inhibits the ability of EL to influence the metabolism of HDL in vivo.
Collapse
Affiliation(s)
- Uli C Broedl
- Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
| | | | | | | | | |
Collapse
|
37
|
Chan DC, Watts GF, Nguyen MN, Barrett PHR. Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr 2006; 84:37-43. [PMID: 16825679 DOI: 10.1093/ajcn/84.1.37] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Disturbed HDL metabolism in insulin-resistant, obese subjects may account for an increased risk of cardiovascular disease. Fish oils and atorvastatin increase plasma HDL cholesterol, but the underlying mechanisms responsible for this change are not fully understood. OBJECTIVE We studied the independent and combined effects of fish oils and atorvastatin on the metabolism of HDL apolipoprotein A-I (apo A-I) and HDL apo A-II in obese men. DESIGN We conducted a 6-wk randomized, placebo-controlled, 2 x 2 factorial intervention study of the effects of fish oils (4 g/d) and atorvastatin (40 mg/d) on the kinetics of HDL apo A-I and HDL apo A-II in 48 obese men with dyslipidemia with intravenous administration of [d3]-leucine. Isotopic enrichments of apo A-I and apo A-II were measured with gas chromatography-mass spectrometry with kinetic parameters derived from a multicompartmental model (SAAM II). RESULTS Fish oils and atorvastatin significantly decreased plasma triacylglycerols and increased HDL cholesterol and HDL2 cholesterol (P < 0.05 for main effects). A significant (P < 0.02) main effect of fish oils was observed in decreasing the fractional catabolic rate of HDL apo A-I and HDL apo A-II. This was coupled with a significant decrease in the corresponding production rates, accounting for a lack of treatment effect on plasma concentrations of apo A-I and apo A-II. Atorvastatin did not significantly alter the concentrations or kinetic parameters of HDL apo A-I and HDL apo A-II. None of the treatments altered insulin resistance. CONCLUSIONS Fish oils, but not atorvastatin, influence HDL metabolism chiefly by decreasing both the catabolism and production of HDL apo A-I and HDL apo A-II in insulin-resistant obese men. Addition of atorvastatin to treatment with fish oils had no additional effect on HDL kinetics compared with fish oils alone.
Collapse
Affiliation(s)
- Dick C Chan
- Metabolic Research Centre, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia
| | | | | | | |
Collapse
|
38
|
Pérez-Méndez O, Duhal N, Lacroix B, Bonte JP, Fruchart JC, Luc G. Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene. Clin Chim Acta 2006; 368:149-54. [PMID: 16487502 DOI: 10.1016/j.cca.2005.12.038] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2005] [Revised: 11/18/2005] [Accepted: 12/21/2005] [Indexed: 11/23/2022]
Abstract
BACKGROUND Lipoprotein lipase (LPL) deficiency has been suggested as a cause of low HDL-cholesterol (HDL-C) plasma levels, by a mechanism that involves an enhanced catabolism of HDL apolipoprotein (apo) AI. To verify the role of 2 different LPL gene mutations on HDL metabolism, we studied the in vivo turnover of the apo AI and apo AII in heterozygous carriers of LPL deficiency. METHODS Apo AI and AII kinetics were studied by a 10-h primed constant infusion of 5,5,5-2H3-leucine approach in 2 carriers, 1 man (patient 1) and 1 woman (patient 2), and 5 control subjects. The rates of HDL apolipoproteins production (PR) and catabolism (FCR) were estimated using a one-compartment model-based analysis. RESULTS Both carriers had low HDL-C plasma levels and only patient 1 was hypertriglyceridemic. VLDL apo B was 4-times slower in patient 1 as compared to patient 2. The FCRs of apo AI in both carriers was within the range of the controls (0.200, 0.221 and 0.211+/-0.051 day(-1), respectively). Apo AII FCR in patient 1 was about 20% lower than the mean of the control group whereas being normal in patient 2. Apo AI PR in patient 1 (9.20 mg kg(-1) day(-1)) was below the lowest value in controls (range, 10.52-13.24 mg kg(-1) day(-1)) whereas in patient 2 it was normal. Apo AII PR in both patients was similar to controls. CONCLUSION The heterozygous carriers of 2 different mutations in the LPL gene had different VLDL apo B FCR, and from normal to slightly low HDL apolipoprotein FCR and PR. These results disagree with the putative enhanced apo AI FCR in LPL deficient patients and suggest the need to reconsider the effects of LPL activity on HDL metabolism.
Collapse
Affiliation(s)
- Oscar Pérez-Méndez
- Department of Atherosclerosis, INSERM U545, Institut Pasteur de Lille, Lille, France.
| | | | | | | | | | | |
Collapse
|
39
|
Zhang H, Sawashita J, Fu X, Korenaga T, Yan J, Mori M, Higuchi K. Transmissibility of mouse AApoAII amyloid fibrils: inactivation by physical and chemical methods. FASEB J 2006; 20:1012-4. [PMID: 16549653 DOI: 10.1096/fj.05-4890fje] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
AApoAII amyloid fibrils have exhibited prion-like transmissibility in mouse senile amyloidosis. We have demonstrated that AApoAII is extremely active and can induce amyloidosis following doses less than 1 pg. We tested physical and chemical methods to disrupt AApoAII fibrils in vitro as determined by thioflavin T binding and electron microscopy (EM) as well as inactivating the transmissibility of AApoAII fibrils in vivo. Complete disruption of AApoAII fibrils was achieved by treatment with formic acid, 6 M guanidine hydrochloride, and autoclaving in an alkaline solution. Injection of these disrupted AApoAII fibrils did not induce amyloidosis in mice. Disaggregation with 6 M urea, autoclaving, and alkaline solution was incomplete, and injection of these AApoAII fibrils induced mild amyloidosis. Treatment with formalin, delipidation, freeze-thaw, and RNase did not have any major effect. A distinct correlation was obtained between the amounts of amyloid fibrils and the transmissibility of amyloid fibrils, thereby indicating the essential role of fibril conformation for transmission of amyloidosis. We also studied the inactivation of AApoAII fibrils by several organic compounds in vitro and in vivo. AApoAII amyloidosis provides a valuable system for studying factors that may prevent transmission of amyloid disease as well as potential novel therapies.
Collapse
Affiliation(s)
- Huanyu Zhang
- Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, Japan
| | | | | | | | | | | | | |
Collapse
|
40
|
Korenaga T, Yan J, Sawashita J, Matsushita T, Naiki H, Hosokawa M, Mori M, Higuchi K, Fu X. Transmission of amyloidosis in offspring of mice with AApoAII amyloidosis. Am J Pathol 2006; 168:898-906. [PMID: 16507905 PMCID: PMC1606535 DOI: 10.2353/ajpath.2006.050350] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 11/17/2005] [Indexed: 11/20/2022]
Abstract
Pre-existing amyloid fibrils can induce further polymerization of endogenous precursor proteins in vivo. Thus, transmission of amyloid fibrils (AApoAII) may induce a conformational change in endogenous apolipoprotein A-II and accelerate amyloid deposition in mouse senile amyloidosis. To characterize transmissibility, we examined amyloidosis in the offspring of AApoAII-injected mother mice that possessed the amyloidogenic Apoa2(c) allele of the apolipoprotein A-II gene. At 4 months of age, amyloid deposits were detected in the intestines of offspring born from and nursed by amyloid fibril-injected mothers, with intensity of deposition increasing thereafter. No amyloid deposits were detected in the offspring of noninjected control mothers. Accelerated amyloidosis was also observed in offspring born from mothers without injection but nursed by amyloid fibril-injected mothers. However, this was not observed in offspring born from amyloid fibril-injected mothers but nursed by control mothers. This fostering excluded vertical transmission through the placenta, suggesting the presence of factors that accelerate amyloidosis during the nursing period. In addition, milk obtained from amyloid fibril-injected mothers induced AApoAII amyloidosis in young mice, and transmission electron microscopy detected noodle-like amyloid fibrils in milk of amyloid fibril-injected mothers. These results provide important insight into the etiology and pathogenesis of amyloid diseases.
Collapse
Affiliation(s)
- Tatsumi Korenaga
- Department of Aging Biology, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Asahi 3-1-1, Matsumoto 390-8621, Japan
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Courtney HS, Zhang YM, Frank MW, Rock CO. Serum opacity factor, a streptococcal virulence factor that binds to apolipoproteins A-I and A-II and disrupts high density lipoprotein structure. J Biol Chem 2006; 281:5515-21. [PMID: 16407233 DOI: 10.1074/jbc.m512538200] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Serum opacity factor (SOF) is a virulence determinant of group A streptococci that opacifies mammalian sera. We analyzed the specificity and mechanism of the opacity reaction using a recombinant form of the amino-terminal opacification domain of SOF, rSOF. Our data indicate that rSOF is neither a protease nor a lipase, but rather it is the binding of rSOF to high density lipoprotein (HDL) that triggers the opacity reaction. rSOF did not opacify plasma from apoA-I(-/-) mice or purified low or very low density lipoproteins but readily opacified HDL. rSOF binding to HDL was characterized by two high affinity binding sites; it bound to apoA-I (K(d) = 6 nm) and apoA-II (K(d) = 30 nm), and both apoA-I and apoA-II blocked the binding of rSOF to HDL. Electron microscopic examination and biochemical analyses of HDL treated with rSOF revealed the formation of lipid droplets devoid of apolipoproteins. Thus, SOF interacts with HDL in human blood by binding to apoA-I and apoA-II and causing the release of HDL lipid cargo, which coalesces to form lipid droplets, resulting in opacification. The disruption of HDL may attenuate its anti-inflammatory functions and contribute to the pathogenesis of group A streptococcal infections.
Collapse
Affiliation(s)
- Harry S Courtney
- Veterans Affairs Medical Center and Department of Medicine, University of Tennessee Health Science Center, 1030 Jefferson Avenue, Memphis, TN 38104, USA.
| | | | | | | |
Collapse
|
42
|
Abstract
We examined the transmissibility of amyloidosis by the implantation of amyloid-containing tissue. If the transmissibility similar to prion diseases is applicable, using amyloid-containing tissue for transplantation in humans might be a risk factor. In this study, AA amyloidosis occurred in mice that underwent implantation of AA amyloid-containing grafts to the liver and subsequent inflammatory stimulation. AApoAII amyloidosis occurred after implantation of AApoAII amyloid-containing grafts to the liver or to the subcutaneous space without inflammatory stimulation. Both types of amyloidoses occurred in the recipient mice sooner than expected. Moreover, AA and AApoAII amyloid deposits were found at 12 weeks after implantation in mice given AApoAII amyloid-containing grafts and inflammatory stimulation. These results suggest that implanted amyloid deposits have an AEF effect and that implanted amyloid-containing tissue can promote and accelerate a different type of amyloidosis. In another experiment, mice received amyloid-containing or normal tissue grafts. The degree of amyloid deposition was compared after 6 days and 5 weeks of inflammatory stimulation and when the mice were killed. There was no obvious difference in the degree of amyloid deposition between each group, indicating that the lag-time is shortened by implantation of amyloid-containing tissue, resulting in severe amyloidosis in the short term.
Collapse
Affiliation(s)
- Sayako Ono
- First Department of Pathology, Yamaguchi University Hospital, Japan.
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Davidson WS, Ghering AB, Beish L, Tubb MR, Hui DY, Pearson K. The biotin-capture lipid affinity assay: a rapid method for determining lipid binding parameters for apolipoproteins. J Lipid Res 2005; 47:440-9. [PMID: 16267343 DOI: 10.1194/jlr.d500034-jlr200] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The lipid affinity of plasma apolipoproteins is an important modulator of lipoprotein metabolism. Mutagenesis techniques have been widely used to modulate apolipoprotein lipid affinity for studying biological function, but the approach requires rapid and reliable lipid affinity assays to compare the mutants. Here, we describe a novel method that measures apolipoprotein binding to a standardized preparation of small unilamellar vesicles (SUVs) containing trace biotinylated and fluorescent phospholipids. After a 30 min incubation at various apolipoprotein concentrations, vesicle-bound protein is rapidly separated from free protein on columns of immobilized streptavidin in a 96-well microplate format. Vesicle-bound protein and lipid are eluted and measured in a fluorescence microplate reader for calculation of a dissociation constant and the maximum number of potential binding sites on the SUVs. Using human apolipoprotein A-I (apoA-I), apoA-IV, and mutants of each, we show that the assay generates binding constants that are comparable to other methods and is reproducible across time and apolipoprotein preparations. The assay is easy to perform and can measure triplicate binding parameters for up to 10 separate apolipoproteins in 3.5 h, consuming only 120 microg of apolipoprotein in total. The benefits and potential drawbacks of the assay are discussed.
Collapse
Affiliation(s)
- W Sean Davidson
- Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45237-0507, USA.
| | | | | | | | | | | |
Collapse
|
44
|
Mercado PA, Ayala YM, Romano M, Buratti E, Baralle FE. Depletion of TDP 43 overrides the need for exonic and intronic splicing enhancers in the human apoA-II gene. Nucleic Acids Res 2005; 33:6000-10. [PMID: 16254078 PMCID: PMC1270946 DOI: 10.1093/nar/gki897] [Citation(s) in RCA: 187] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2005] [Revised: 09/19/2005] [Accepted: 09/27/2005] [Indexed: 01/11/2023] Open
Abstract
Exon 3 of the human apolipoprotein A-II (apoA-II) gene is efficiently included in the mRNA although its acceptor site is significantly weak because of a peculiar (GU)16 tract instead of a canonical polypyrimidine tract within the intron 2/exon 3 junction. Our previous studies demonstrated that the SR proteins ASF/SF2 and SC35 bind specifically an exonic splicing enhancer (ESE) within exon 3 and promote exon 3 splicing. In the present study, we show that the ESE is necessary only in the proper context. In addition, we have characterized two novel sequences in the flanking introns that modulate apoA-II exon 3 splicing. There is a G-rich element in intron 2 that interacts with hnRNPH1 and inhibits exon 3 splicing. The second is a purine rich region in intron 3 that binds SRp40 and SRp55 and promotes exon 3 inclusion in mRNA. We have also found that the (GU) repeats in the apoA-II context bind the splicing factor TDP-43 and interfere with exon 3 definition. Significantly, blocking of TDP-43 expression by small interfering RNA overrides the need for all the other cis-acting elements making exon 3 inclusion constitutive even in the presence of disrupted exonic and intronic enhancers. Altogether, our results suggest that exonic and intronic enhancers have evolved to balance the negative effects of the two silencers located in intron 2 and hence rescue the constitutive exon 3 inclusion in apoA-II mRNA.
Collapse
Affiliation(s)
- Pablo Arrisi Mercado
- International Centre for Genetic Engineering and BiotechnologyPadriciano 99, I-34012 Trieste, Italy
| | - Youhna M. Ayala
- International Centre for Genetic Engineering and BiotechnologyPadriciano 99, I-34012 Trieste, Italy
| | - Maurizio Romano
- International Centre for Genetic Engineering and BiotechnologyPadriciano 99, I-34012 Trieste, Italy
- Department of Physiology and Pathology, University of TriesteVia A. Fleming 22, 34127 Trieste, Italy
| | - Emanuele Buratti
- International Centre for Genetic Engineering and BiotechnologyPadriciano 99, I-34012 Trieste, Italy
| | - Francisco E. Baralle
- International Centre for Genetic Engineering and BiotechnologyPadriciano 99, I-34012 Trieste, Italy
| |
Collapse
|
45
|
de Beer MC, van der Westhuyzen DR, Whitaker NL, Webb NR, de Beer FC. SR-BI-mediated selective lipid uptake segregates apoA-I and apoA-II catabolism. J Lipid Res 2005; 46:2143-50. [PMID: 16061955 DOI: 10.1194/jlr.m500068-jlr200] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The HDL receptor scavenger receptor class B type I (SR-BI) binds HDL and mediates the selective uptake of cholesteryl ester. We previously showed that remnants, produced when human HDL(2) is catabolized in mice overexpressing SR-BI, become incrementally smaller, ultimately consisting of small alpha-migrating particles, distinct from pre-beta HDL. When mixed with mouse plasma, some remnant particles rapidly increase in size by associating with HDL without the mediation of cholesteryl ester transfer protein, LCAT, or phospholipid transfer protein. Here, we show that processing of HDL(2) by SR-BI-overexpressing mice resulted in the preferential loss of apolipoprotein A-II (apoA-II). Short-term processing generated two distinct, small alpha-migrating particles. One particle (8.0 nm diameter) contained apoA-I and apoA-II; the other particle (7.7 nm diameter) contained only apoA-I. With extensive SR-BI processing, only the 7.7 nm particle remained. Only the 8.0 nm remnants were able to associate with HDL. Compared with HDL(2), this remnant was more readily taken up by the liver than by the kidney. We conclude that SR-BI-generated HDL remnants consist of particles with or without apoA-II and that only those containing apoA-II associate with HDL in an enzyme-independent manner. Extensive SR-BI processing generates small apoA-II-depleted particles unable to reassociate with HDL and readily taken up by the liver. This represents a pathway by which apoA-I and apoA-II catabolism are segregated.
Collapse
Affiliation(s)
- Maria C de Beer
- Graduate Center for Nutritional Sciences, University of Kentucky Medical Center, Lexington, KY 40536, USA
| | | | | | | | | |
Collapse
|
46
|
Rotllan N, Ribas V, Calpe-Berdiel L, Martín-Campos JM, Blanco-Vaca F, Escolà-Gil JC. Overexpression of Human Apolipoprotein A-II in Transgenic Mice Does Not Impair Macrophage-Specific Reverse Cholesterol Transport In Vivo. Arterioscler Thromb Vasc Biol 2005; 25:e128-32. [PMID: 15994442 DOI: 10.1161/01.atv.0000175760.28378.80] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background—
Overexpression of human apolipoprotein (apo) A-II in transgenic mice induces high-density lipoprotein (HDL) deficiency, and increased atherosclerosis susceptibility only when fed an atherogenic diet. This may, in part, be caused by impairment in reverse cholesterol transport (RCT).
Methods and Results—
[
3
H]cholesterol-labeled macrophages were injected intraperitoneally into mice maintained on a chow diet or an atherogenic diet. Plasma [
3
H]cholesterol did not differ from human apoA-II transgenic and control mice at 24 or 48 hours after the label injection. On the chow diet, human apoA-II transgenic mice presented increased [
3
H]cholesterol in liver (1.3-fold) and feces (6-fold) compared with control mice (
P
<0.05). The magnitude of macrophage-specific RCT did not differ between transgenic and control mice fed the atherogenic diet.
Conclusions—
Human apoA-II maintains effective RCT from macrophages to feces in vivo despite an HDL deficiency. These findings suggest that the increased atherosclerotic lesions observed in apoA-II transgenic mice fed an atherogenic diet are not caused by impairment in macrophage-specific RCT.
Collapse
Affiliation(s)
- Noemí Rotllan
- Servei de Bioquímica, Institut de Recerca, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
47
|
Hunter M, Angelicheva D, Tournev I, Ingley E, Chan DC, Watts GF, Kremensky I, Kalaydjieva L. NDRG1 interacts with APO A-I and A-II and is a functional candidate for the HDL-C QTL on 8q24. Biochem Biophys Res Commun 2005; 332:982-92. [PMID: 15922294 DOI: 10.1016/j.bbrc.2005.05.050] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2005] [Accepted: 05/07/2005] [Indexed: 02/08/2023]
Abstract
Hereditary Motor and Sensory Neuropathy Lom (HMSNL) is a severe autosomal recessive peripheral neuropathy, the most common form of demyelinating Charcot-Marie-Tooth (CMT) disease in the Roma (Gypsy) population. The mutated gene, N-myc downstream-regulated gene 1 (NDRG1), is widely expressed and has been implicated in a range of processes and pathways. To gain an insight into NDRG1 function we performed yeast two-hybrid screening and identified interacting proteins whose known functions suggest involvement in cellular trafficking. Further analyses, focusing on apolipoproteins A-I and A-II, confirmed their interaction with NDRG1 in mammalian cells and suggest a defect in Schwann cell lipid trafficking as a major pathogenetic mechanism in HMSNL. At the same time, the chromosomal location of NDRG1 coincides with a reported HDL-C QTL in humans and in mice. A putative role of NDRG1 in the general mechanisms of HDL-mediated cholesterol transport was supported by biochemical studies of blood lipids, which revealed an association between the Gypsy founder mutation, R148X, and decreased HDL-C levels.
Collapse
Affiliation(s)
- Michael Hunter
- Laboratory for Molecular Genetics, Western Australian Institute for Medical Research and Centre for Medical Research, The University of Western Australia, Nedlands 6009, Australia
| | | | | | | | | | | | | | | |
Collapse
|
48
|
Cui XY, Fang DZ. [The role of liver on hypertriglyceridemia]. Sheng Li Ke Xue Jin Zhan 2005; 36:166-9. [PMID: 16222982] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
|
49
|
Desroches S, Paradis ME, Pérusse M, Archer WR, Bergeron J, Couture P, Bergeron N, Lamarche B. Apolipoprotein A-I, A-II, and VLDL-B-100 metabolism in men. J Lipid Res 2004; 45:2331-8. [PMID: 15342678 DOI: 10.1194/jlr.m400287-jlr200] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The impact of a low-fat diet and a high-MUFA diet on apolipoprotein A-I (apoA-I), apoA-II, and VLDL-apoB-100 metabolism in conditions of unrestricted (ad libitum) energy intake was compared in 65 men randomly assigned to one of two predefined experimental diets. A subsample of 18 men participated in the kinetic study. Before and after the 6-7 week dietary intervention, kinetic subjects received a primed-constant infusion of [5,5,5-2H3]L-leucine for 12 h under feeding conditions. ApoA-I production rate (PR; -31.5%; P <0.001) and fractional catabolic rate (FCR; -24.3%; P <0.05) were significantly decreased after the low-fat diet. These changes in apoA-I PR and FCR with the low-fat diet were also significantly different from those observed with the high-MUFA diet (P <0.01 and P <0.05, respectively). ApoA-II FCR was significantly increased in the high-MUFA group only. No significant within- or between-diet difference was found in VLDL-apoB-100 PR or FCR. These results emphasize the differential impact of the low-fat diet and high-MUFA diet on HDL metabolism.
Collapse
Affiliation(s)
- Sophie Desroches
- Institute on Nutraceuticals and Functional Foods, Laval University, Ste-Foy, Québec, Canada
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Caiazza D, Jahangiri A, Rader DJ, Marchadier D, Rye KA. Apolipoproteins regulate the kinetics of endothelial lipase-mediated hydrolysis of phospholipids in reconstituted high-density lipoproteins. Biochemistry 2004; 43:11898-905. [PMID: 15362876 DOI: 10.1021/bi049776t] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Endothelial lipase (EL) is a newly identified member of the triglyceride lipase gene family that hydrolyzes high-density lipoprotein (HDL) phospholipids. This study investigates the ability of the major apolipoproteins of rHDL to regulate the kinetics of EL-mediated phospholipid hydrolysis in well-characterized, homogeneous preparations of spherical rHDL. The rHDL contained either apoA-I as the only apolipoprotein, (A-I)rHDL, apoA-II as the only apolipoprotein, (A-II)rHDL, or apoA-I as well as apoA-II, (A-I/A-II)rHDL. The rHDL were comparable in terms of size and lipid composition and contained cholesteryl esters (CE) as their sole core lipid. Phospholipid hydrolysis was quantitated as the mass of nonesterified fatty acids (NEFA) released from the rHDL during incubation with EL. The V(max) of phospholipid hydrolysis for (A-I/A-II)rHDL [391.9 +/- 12.9 nmol of NEFA formed (mL of EL)(-1) h(-1)] was greater than (A-I)rHDL [152.8 +/- 4.7 nmol of NEFA formed (mL of EL)(-1) h(-1)]. The energy of activation (E(a)) for the hydrolysis reactions was calculated to be 52.1 and 34.8 kJ mol(-1) for (A-I)rHDL and (A-I/A-II)rHDL, respectively. Minimal phospholipid hydrolysis was observed for the (A-II)rHDL. Kinetic analysis showed that EL has a higher affinity for the phospholipids in (A-I)rHDL [K(m)(app) = 0.10 +/- 0.01 mM] than in (A-I/A-II)rHDL [K(m)(app) = 0.27 +/- 0.03 mM]. Furthermore, (A-I)rHDL is a competitive inhibitor of the EL-mediated phospholipid hydrolysis of (A-I/A-II)rHDL. These results establish that apolipoproteins are major determinants of the kinetics of EL-mediated phospholipid hydrolysis in rHDL.
Collapse
Affiliation(s)
- Daniela Caiazza
- Lipid Research Group, The Heart Research Institute, Camperdown, Sydney, NSW 2050, Australia.
| | | | | | | | | |
Collapse
|